Onconova remains focused on development of its proprietary pipeline of targeted agents as it enters a new phase as a biopharmaceutical company NEWTOWN, Pa., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing
NEWTOWN, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company plans to participate in several upcoming events: Marcus Evans Healthcare
Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021 NEWTOWN, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat
NEWTOWN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 12 NEWTOWN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today
ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumors Investigator-initiated study advances with combination of oral rigosertib and nivolumab in K-RAS mutated non-small cell lung cancer Actively evaluating strategic opportunities to further enhance our
U.S. Phase 1 trial patient enrollment to begin in the first half of 2021 China Phase 1 trial enrollment ongoing Key regulatory milestone achieved to enable further study of product candidate for patients with HR+ HER 2- metastatic breast cancer and other tumors NEWTOWN, Pa., Nov.
Company affirms plans to begin enrollment of patients with HR+ HER2- metastatic breast cancer and other tumors in U.S. Phase 1 trial in the first half of 2021 NEWTOWN, Pa., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a biopharmaceutical company focused on
NEWTOWN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive purchase agreement with certain
NEWTOWN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, MD, President & CEO, will present a Company
NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten
NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the pricing of an underwritten public offering of 25,000,000 shares of its
NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will present a virtual
NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the closing of its previously-announced underwritten public offering.
NEWTOWN, Pa., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces receipt of notification from Nasdaq that the Company has regained compliance